Bromocriptine and psychosis: A literature review

  title={Bromocriptine and psychosis: A literature review},
  author={Alan Patrick Boyd},
  journal={Psychiatric Quarterly},
  • A. Boyd
  • Published 1995
  • Medicine, Psychology
  • Psychiatric Quarterly
Bromocriptine is an ergot-derived dopamine agonist. Its current uses include the treatment of Parkinson's disease, postpartum ablaction, prolactionmas, acromegaly, and amenorrhea and galactorrhea secondary to neuroleptic use. It is often reported to produce psychiatric side effects such as confusion, hallucinations, and delusions. The literature is reviewed and supports a strong anecdotal relationship between bromocriptine use and psychosis. 
Managing Parkinsonism in a Schizophrenic Patient
A schizophrenic patient with Parkinsonism could not tolerate levodopa-carbidopa without aggravating her psychosis, but the rotigitine patch markedly improved extrapyramidal features without worsening her schizophrenia.
Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital
The addition of aripiprazole can reduce prolactin levels and restore sexual function in patients maintained on depot medication and demonstrate the potential role of the drug in a forensic setting.
Transient psychosis in women on clomiphene, bromocriptine, domperidone and related endocrine drugs
  • M. Seeman
  • Medicine, Psychology
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2015
In susceptible women, psychotic symptoms can result from treatments that reduce estrogen levels, such as leuprolide acetate or clomiphene, or treatments that increase dopamine levels (bromocriptine), and estrogen-reducing and dopamine-increasing treatments used in gynecology need to be carefully monitored.
Treatment Complexities of a Young Woman Suffering Psychosis and Pituitary Adenoma
The case highlights the importance of the role of prolactin in psychosis and of an interdisciplinary team approach when patients present with complex symptoms.
Cabergoline-induced manic episode: case report
The first manic episode occurring after cabergoline use for hyperprolactinemia treatment is reported, reporting the first knowledge in the literature of dopamine agonist-induced mania.
Taurine Implicated in Bromocriptine Induced Hallucination: Glycine-Glutamic-Aspartic Implicated in Bromocriptine Induced Schizophrenia
Evidence for the possible involvement of some amino acids in mediating some actions of bromocriptine is provided, which indicates that different mechanisms of the etiology of schizophrenia which are not possible based upon dopaminergic mechanism alone.
Letter to the Editors Correspondance
The role of caber-goline as a new treatment to inhibit lactation in patients with psychosis, as well as in its mechanism of action compared with other ergot deriva-tives used for this purpose are investigated.
Prolactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorder
Three patients with psychoses and concomitant prolactin-secreting pituitary tumours are described, supporting the view that neuroleptics being dopamine antagonists and dopamine agonistic agents which are the primary treatment of Prolactinomas can cancel out each other’s effects.
Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists
  • R. Holt
  • Medicine, Biology
    Journal of psychopharmacology
  • 2008
The administration of antipsychotic medication is responsible for the high prevalence of hyperprolactinaemia in people with severe mental illness and should be distinguished from pathological causes to prevent unnecessary investigation and treatment.
Psychosis in Parkinson's disease: therapeutic options.
There is a considerable need to further study the existing drugs and explore other pharmacotherapies in Parkinson's disease psychosis to ensure sound methodological quality and control for confounding variables to provide results that could be used reliably in clinical practice.


Bromocriptine-induced psychosis in acromegaly.
The following case is of interest because of the insidious onset of psychosis and the family history of paranoid schizophrenia.
Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia.
A case involving a patient with neuroleptic-induced remission of psychiatric symptoms in whom bromocriptine was associated with temporary exacerbation of schizophrenic symptoms is reported.
Postpartum psychosis induced by bromocriptine.
Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation, demonstrating that bromOCriptine may cause psychosis even when given in low doses.
Psychotic reactions during treatment of pituitary tumours with dopamine agonists.
Of 600 patients treated with the dopamine agonist drugs bromocriptine and lisuride for functioning pituitary tumours, eight developed drug related psychoses. Symptoms included auditory
Psychotic exacerbation attributed to low‐dose bromocriptine treatment of galactorrhea and hyperprolactinemia
Advice is given in the use of bromocriptine especially in patients with a pre‐existing psychiatric history and monitoring for changes in mental status when bromoriptine is prescribed.
Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
A case history is presented where it occurred together with hyperkinesias while the patient was treated with L-dopa and bromocriptine and he developed several paranoid-hallucinatory psychoses which subsided each time upon dose reduction.
Bromocriptine-related psychosis and treatment
Drugs five years later. Bromocriptine.
Withdrawal of bromocriptine therapy is associated in most patients with reversal of its beneficial effects--return of hyperprolactinemia, return of excess growth hormone secretion, and exacerbation of Parkinson's disease.
Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma.
The Behavioral Toxicity of Bromocriptine in Patients with Psychiatric Illness
Bromocriptine can be safely used in patients at risk for psychotic illnesses as long as patients are clinically stable and maintained on neuroleptics, according to the results of a double-blind study.